IBM: platform for clinital trials against Covid
(CercleFinance.com) - The American immuno-oncology company Oncotelic announced on Wednesday that IBM had offered it free access to its clinical research platform as part of its project to develop treatment for Covid-19.
With the coronavirus crisis, IBM has recently started offering biotech companies the possibility of using its electronic data platform "IBM Clinical Development" free of charge, which aims to reduce the duration and cost of clinical trials.
iBio, an American laboratory that develops plant-based drugs, has also been granted 18 months' access to this artificial intelligence platform derived from IBM Watson to accelerate its research for a vaccine against Covid.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
With the coronavirus crisis, IBM has recently started offering biotech companies the possibility of using its electronic data platform "IBM Clinical Development" free of charge, which aims to reduce the duration and cost of clinical trials.
iBio, an American laboratory that develops plant-based drugs, has also been granted 18 months' access to this artificial intelligence platform derived from IBM Watson to accelerate its research for a vaccine against Covid.
Copyright (c) 2020 CercleFinance.com. All rights reserved.